Literature DB >> 22375995

Vemurafenib sensitivity skin reaction after ipilimumab.

James J Harding, Melissa Pulitzer, Paul B Chapman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22375995     DOI： 10.1056/NEJMc1114329

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  29 in total

1.  Increased treatment-related toxicity subsequent to an anti-PD-1 agent.

Authors:  Leila Khoja; Marcus Ortho Butler; Mary Anne Chappell; David Hogg; Anthony M Joshua
Journal:  Curr Oncol       Date:  2015-08       Impact factor: 3.677

2.  Vemurafenib acts as an aryl hydrocarbon receptor antagonist: Implications for inflammatory cutaneous adverse events.

Authors:  Heike C Hawerkamp; Andreas Kislat; Peter A Gerber; Marius Pollet; Katharina M Rolfes; Anatoly A Soshilov; Michael S Denison; Afaque A Momin; Stefan T Arold; Angeliki Datsi; Stephan A Braun; Péter Oláh; Mario E Lacouture; Jean Krutmann; Thomas Haarmann-Stemmann; Bernhard Homey; Stephan Meller
Journal:  Allergy       Date:  2019-09-03       Impact factor: 13.146

Review 3.  Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges.

Authors:  Siwen Hu-Lieskovan; Lidia Robert; Blanca Homet Moreno; Antoni Ribas
Journal:  J Clin Oncol       Date:  2014-06-23       Impact factor: 44.544

4.  [Targeted therapies for melanoma].

Authors:  U Leiter; F Meier; C Garbe
Journal:  Hautarzt       Date:  2014-07       Impact factor: 0.751

5.  Melanoma brain metastases and vemurafenib: need for further investigation.

Authors:  Nicole M Rochet; Roxana S Dronca; Lisa A Kottschade; Rahul N Chavan; Brian Gorman; Julie R Gilbertson; Svetomir N Markovic
Journal:  Mayo Clin Proc       Date:  2012-10       Impact factor: 7.616

6.  From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely.

Authors:  Daphne Day; Arta M Monjazeb; Elad Sharon; S Percy Ivy; Eric H Rubin; Gary L Rosner; Marcus O Butler
Journal:  Clin Cancer Res       Date:  2017-09-01       Impact factor: 12.531

7.  A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105.

Authors:  Alexander Drilon; Siqing Fu; Manish R Patel; Marwan Fakih; Ding Wang; Anthony J Olszanski; Daniel Morgensztern; Stephen V Liu; Byoung Chul Cho; Lyudmila Bazhenova; Cristina P Rodriguez; Robert C Doebele; Antoinette Wozniak; Karen L Reckamp; Tara Seery; Petros Nikolinakos; Zheyi Hu; Jennifer W Oliver; Denise Trone; Katherine McArthur; Rupal Patel; Pratik S Multani; Myung-Ju Ahn
Journal:  Cancer Discov       Date:  2018-11-28       Impact factor: 39.397

8.  Rapid recovery of postnivolumab vemurafenib-induced Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome after tocilizumab and infliximab administration.

Authors:  Natalia Maximova; Alessandra Maestro; Davide Zanon; Annalisa Marcuzzi
Journal:  J Immunother Cancer       Date:  2020-02       Impact factor: 13.751

9.  Appearance of New Vemurafenib-associated Melanocytic Nevi on Normal-appearing Skin: Case Series and a Review of Changing or New Pigmented Lesions in Patients with Metastatic Malignant Melanoma After Initiating Treatment with Vemurafenib.

Authors:  Philip R Cohen; Agop Y Bedikian; Kevin B Kim
Journal:  J Clin Aesthet Dermatol       Date:  2013-05

10.  Fibroblasts protect melanoma cells from the cytotoxic effects of doxorubicin.

Authors:  Manoela Tiago; Edson Mendes de Oliveira; Carla Abdo Brohem; Paula Comune Pennacchi; Rafael Duarte Paes; Raquel Brandão Haga; Ana Campa; Silvia Berlanga de Moraes Barros; Keiran S Smalley; Silvya Stuchi Maria-Engler
Journal:  Tissue Eng Part A       Date:  2014-03-25       Impact factor: 3.845
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.